Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8633194 | CHATTEM SANOFI | Pharmaceutical composition of piperazine derivatives |
Oct, 2027
(4 years from now) |
Xyzal Allergy 24Hr is owned by Chattem Sanofi.
Xyzal Allergy 24Hr contains Levocetirizine Dihydrochloride.
Xyzal Allergy 24Hr has a total of 1 drug patent out of which 0 drug patents have expired.
Xyzal Allergy 24Hr was authorised for market use on 31 January, 2017.
Xyzal Allergy 24Hr is available in solution;oral dosage forms.
The generics of Xyzal Allergy 24Hr are possible to be released after 16 October, 2027.
Drugs and Companies using LEVOCETIRIZINE DIHYDROCHLORIDE ingredient
Market Authorisation Date: 31 January, 2017
Treatment: NA
Dosage: SOLUTION;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic